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HLA matching is not currently described consistently in the
hematopoietic stem cell transplant outcomes literature. Terms like
“high-resolution” are often used with different underlying mean-
ings. As the question of the clinical impact of various degrees of
HLA matching is investigated in detail, it is useful to have a
consistent deﬁnition so that studies can be compared. We propose
a deﬁnition of HLA matching that is based on 2 assignments per
locus (1 for each allele) and with 4 degrees of match per assignment
based on the resolution of the available HLA typing: HM—high-
resolution match, Hmm—high-resolution mismatch (low/inter-
mediate resolution match), IM—intermediate/low resolution
match, Imm—intermediate/low resolution mismatch. High-reso-
lution matching between two high-resolution HLA types is deﬁned
as follows: (1) a unique 4-digit HLA allele; (2) a combination of
possible HLA alleles that share the same antigen-binding domain;
and (3) a combination of possible alleles where only one is deﬁned
as being non-rare (eg, DRB11501 or 1509 compared to
DRB11501 or 1508 since DRB11508 and DRB11509 ﬁt the
deﬁnition of rare). Identity in the antigen-binding domains is based
on identical protein sequences encoded by exon 2 for Class II and
exons 2 and 3 for Class I. The deﬁnition of non-rare is an allele that
occurs at a frequency of greater than or equal to 1/100,000 for
HLA-DRB1 or 1/50,000 for HLA-A, -C, -B, and -DQB1 in the
National Marrow Donor Program (NMDP) database. Intermedi-
ate/low resolution matching is deﬁned using either serologic types
or serologic equivalents determined from DNA-based types. The
World Marrow Donor Association—Information Technology
Working Group has deﬁned an electronic reference (http://www.
anthonynolan.org.uk/HIG/nomen/wmda.html) for DNA allele,
serologic relationships, DNA-serology relationships, and HLA al-
leles with equivalent “antigen-binding domains”. The NMDP has
made an electronic reference available for alleles that are rare
within the NMDP database (http://www.nmdpresearch.org/HLA/
allele_tally.html). This set of deﬁnitions is intended to promote
consistency in approach and ease of incorporating a matching
analysis into non-HLA focused studies, eg, disease speciﬁc, treat-
ment speciﬁc, or analyses of other immunogenetic loci (KIR, cy-
tokines, mHAgs, etc. . .), and has been adopted for use by the
Center for International Blood and Marrow Transplant Research
(CIBMTR) and the NMDP.
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delphia, PA.
Clinical experience and animal models have shown that donor T
cell depletion adversely effects engraftment of hematopoietic stem
cells. While it is likely that donor T cells are acting to overcome
residual host immune barriers, they may also exert effects indepen-
dent of host resistance via direct or indirect interactions with stem
cells and/or the stem cell niche. In order to more precisely deﬁne
the effect of T cells on engraftment, we have performed human
umbilical cord blood (UCB) transplants into B2microglobulin/
/NOD/SCID mice under limiting dilution conditions, and eval-
uated the transplanted mice for both short and longer term hema-
topoietic engraftment. UCB mononuclear cells (MNC) or UCB
depleted of T cells using CD2 immunomagnetic separation were
transplanted into sub-lethally irradiated (300 cGy)
B2microglobulin//NOD/SCID mice. CD3 T cells com-
prised 34% of CB MNC and 1.2% of T cell depleted (TCD) UCB.
Cohorts of mice received UCB MNC or TCD UCB at 5 dose
levels between 5  104 and 5  106 total cells, with CD34 cells
comprising 0.58% of TCD UCB and 0.39% of UCB MNC.
Percent human CD45 cells in bone marrow were analyzed by
ﬂow cytometry to assess for engraftment between days 22 to 27 or
39 to 45 post-transplantation. Overall, mean engraftment in the
UCB MNC recipients (n 27) was 6.25% (range 0–29.8%) versus
2.2% (range 0–12.8%) in the TCD UCB recipients (n  22) (P 
.033). For both MNC and TCD recipients, engraftment was 1%
at the 5  104 cell dose and increased with increasing cell dose. At
each dose level at or above 105 cells, engraftment was higher in
recipients of UCBMNC. These results, in a model where there are
minimal host immune barriers to overcome, suggest that T cells
possess additional graft-facilitating properties. Further experi-
ments in this model will be used to evaluate the role of T cell
subsets and in vitro T cell activation on the short- and long-term
engraftment of UCB.
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Since the ﬁrst successful cord blood stem cell transplantation
(CBSCT) for a pediatric patient with relapsed ALL in April 1998,
the cases of CBSCT have been increasing in Korea. The medical
insurance for CBSCT in children aged less than 15 years has been
covered since January 2003, when the cases of pediatric CBSCT
have been abruptly increased. We analyzed the data of 163 pedi-
atric patients who received CBSCT at 13 transplant centers be-
tween Oct 1996 and April 2005. A minority of patients (n  11)
received double cord blood units. The median age and weight of
recipients were 6.4 years (range, 0.6–16.9 years) and 21 kg (range,
7–67.8 kg), respectively. The diagnosis was as follows: acute leu-
kemia (n 114), SAA (n 12), genetic or metabolic disorders (n
11), Fanconi anemia (n  7), JMML (n  7), CML (n  5), MDS
(n  4), and solid tumors (n  3). The median infused nucleated
cell dose was 4.5 107/kg (range, 0.27–13.6 107/kg). Neutrophil
recovery was attained in 144 patients (88.3%) at a median of 19
days (range, 10–62 days). Notably, all 11 patients receiving double
units engrafted successfully. It took 45 days (range, 14–394 days)
for platelet recovery in 119 patients. Grade 2–4 and grade 3–4
acute GVHD were developed in 40% and 12.6% of patients,
respectively. Nineteen out of the 90 evaluable patients (21.1%)
developed chronic GVHD (10 limited, 9 extensive). The incidence
of acute GVHDgrade 2 was higher in the 2-antigen mismatched
group compared with that of the 0- or 1-antigen mismatched
group (P  .03), but the incidence of chronic GVHD was not
different between each groups (P  .1). The 7-year overall and
event-free survival was 50.6% and 39.0%, respectively, and there
was no survival difference between 0- or 1-antigen mismatched
transplants and 2-antigen mismatched ones (P  .21). Transplant-
related causes (n  48) were responsible for the 72.7% of all
mortalities. Our results suggest that special efforts should be made
to reduce the transplant-related mortality for the better outcome of
CBSCT.
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